Blockbuster Biologics Review, produced by our intellectual property lawyers, covers developments in inter partes review (IPR) and patent litigation challenges to blockbuster biologic drugs.
These quarterly reports provide updates on the following topics:
- The current status of IPR challenges to blockbuster biologics
- The institution and invalidation rates for IPRs challenging blockbuster biologics
- The current status of patent litigations implicating blockbuster biologics
We will continue to monitor developments and provide updates regularly.
Read the current issue >>
Past Issues
2023
Issue 21 (November 2023) >>
Issue 20 (August 2023) >>
Issue 19 (March 2023) >>
2022
Issue 18 (December 2022) >>
Issue 17 (October 2022) >>
Issue 16 (July 2022) >>
Issue 15 (April 2022) >>
2021
Issue 14 (December 2021) >>
Issue 13 (August 2021) >>
Issue 12 (April 2021) >>
Issue 11 (February 2021) >>
2020
Issue 10 (September 2020) >>
Issue 9 (April 2020) >>
Issue 8 (February 2020) >>
2019
Issue 7 (November 2019) >>
Issue 6 (July 2019) >>
Issue 5 (April 2019) >>
Issue 4 (January 2019) >>
2018
Issue 3 (October 2018) >>
Issue 2 (July 2018) >>
Issue 1 (April 2018) >>
Additional Resources
News
Thought Leadership
- Taking Advantage of the New Purple Book Patent Requirements for Biologics – April 26, 2021
- FDA COVID-19 Guidance Roundup For Drug and Biologics – June 29, 2020
- USPTO Announces Further COVID-19 Relief for Large and Small Entities – June 4, 2020
- Federal Circuit: Inherency in an Obviousness Analysis – January 15, 2020
- Federal Circuit: Open Transitional Phrases and Markush Groups in Pharmaceutical Claims – January 13, 2020
- Federal Circuit: Finding the Safe Harbor in Drug Development’s Choppy Waters – December 24, 2019
- Federal Circuit: ‘Consisting Essentially of’ Risks Indefiniteness and No Intent From ANDA Label’s Permissive Use – October 14, 2019
- Lawmakers Propose Changes to Framework of Sections 101 on Patent Eligibility and 112(f) on Functional Claiming – May 20, 2019
- Cleveland Clinic Foundation v. True Health Diagnostics, LLC – April 3, 2019
- What’s in a Name? FDA Proposes Updates To Its Biosimilar Naming Policy – March 18, 2019
- FDA Sings the Orange Book Blues to Announce a Potential New Patent Listing Approach, As Prescribed Blog Post – March 8, 2019